ATTORNEY DOCKET NO.: 056291-5199 National Stage Application of PCT/GB2002/003390

DT01 Rec'd PCT/PTC 0 8 FEB 2005

## IN THE CLAIMS:

Please amend the claims as follows:

Claim 1 (currently amended): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal—such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically acceptable salt thereof.

Claim 2 (currently amended): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal-such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.

Claim 3 (currently amended): A method for the treatment of a cancer in a warm-blooded animal-such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically acceptable salt thereof.

Claim 4 (currently amended): A method for the treatment of a cancer in a warm-blooded animal-such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.

Claim 5 (**currently amended**): A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal-such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof,

before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically

acceptable salt thereof.

Claim 6 (currently amended): A method for the treatment of a cancer involving a

solid tumour in a warm-blooded animal such as a human, which comprises administering to

said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof,

before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically

acceptable salt thereof and before, after or simultaneously with an effective amount of

ionising radiation.

Claim 7 (original): A pharmaceutical composition which comprises ZD6474 or a

pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt

thereof, in association with a pharmaceutically acceptable excipient or carrier.

Claim 8 (original): A kit comprising ZD6474 or a pharmaceutically acceptable salt

thereof, and ZD1839 or a pharmaceutically acceptable salt thereof.

Claims 9-14 (cancelled).